Gene therapy to human disease: ex vivo and in vivo studies (Review)

International Journal of Oncology

Volumn 9, Issue 6, 1996, Pages 1239-1251

  Boulikas, Teni ^a  

^a Inst of Molecular Medical Sciences   (United States)

Author keywords

1 antitrypsin; adenosine deaminase; angiogenesis; atherosclerosis; cystic fibrosis; hemophilia; lysosomal storage disease; Parkinson's disease; restenosis; TGF ; VEGF; w ound healing

Indexed keywords

ARTICLE; ATHEROSCLEROSIS; CANCER; GENE THERAPY; HEMOPHILIA; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

EID: 0029803652     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (112)

1. Ledley FD: Nonviral gene therapy: The promise of genes as pharmaceutical products. Hum Gene Ther 6: 1129-1144, 1995.
2. Lasic DD, Templeton NS: Liposomes in gene therapy. Adv Drug Del Rev (In press).
3. Anderson WF: Human gene therapy. Science 256: 808-813, 1992.
4. Boulikas T: Cancer gene therapy and immunotherapy. Int J Oncol 9: 941-954, 1996.
5. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP and White DE: Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319: 1676-1680, 1988.
6. Chang AE, Sondak VK, Bishop DK, Nickoloff BJ, Mulligan RC and Mule JJ: Clinical protocol. Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Hum Gene Ther 7: 773-792, 1996.
7. Mayordomo JI, Zorina T, Storkus WJ, Zitvogel L, Celluzzi C, Falo LD, Melief CJ, Ildstad ST, Kast WM, Deleo AB, Lotze MT: Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med 1: 1297-1302, 1995.
8. Yanofsky SD, Baldwin DN, Butler JH, Holden FR, Jacobs JW, Balasubramanian P, Chinn JP, Cwirla SE, Peters-Bhatt E, Whitehorn EA, Tate EH, Akeson A, Bowlin TL, Dower WJ, Barrett RW: High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries. Proc Natl Acad Sci USA 93: 7381-7386, 1996.
9. Doorbar J, Winter G: Isolation of a peptide antagonist to the thrombin receptor using phage display. J Mol Biol 244: 361-369, 1994.
10. Barry MA, Dower WJ, Johnston SA: Toward cell-targeting gene therapy vectors: Selection of cell-binding peptides from random peptide-presenting phage libraries. Nature Med 2: 299-305, 1996.
11. Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD, and Mixson AJ: Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 6: 395-405, 1995.
12. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang W-W, Harper JW and Thompson TC: in vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55: 5151-5155, 1995.
13. Yang C, Cirielli C, Capogrossi MC and Passaniti A: Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 55: 4210-4213, 1995.
14. Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH and Blaese RM: In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256: 1550-1552, 1992.
15. Su H, Chang JC, Xu SM and Kan YW: Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene. Hum Gene Ther 7: 463-470, 1996.
16. Eastham JA, Chen S-H, Sehgal I, Yang G, Timme TL, Hall SJ, Woo SLC and Thompson TC: Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther 7: 515-523, 1996.
17. Kimura H, Sakamoto T, Cardillo JA, Spee C, Hinton DR, Gordon EM, Anderson WF and Ryan SJ: Retrovirus-mediated suicide gene transduction in the vitreous cavity of the eye: Feasibility in prevention of proliferative vitreoretinopathy. Hum Gene Ther 7: 799-808, 1996.
18. Dimaio JM, Clary BM, Via DF, Coveney E, Papas TN and Lyerly HK: Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 116: 205-213, 1994.
19. Osaki T, Tanio Y, Tachibana I, Hosoe S, Kumagai T, Kawase I, Oikawa S, Kishimoto T: Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res 54: 5258-5261, 1994.
20. Richards CA, Austin EA and Huber BE: Transcriptional regulatory sequences of carcinoembryonic antigen: Identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther 6: 881-893, 1995.
21. Blaese RM, Culver KW, Miller AD, Carter CS, Fleisher T, Clerici M, Shearer G, Chang L, Chiang Y, Tolstoshev P, Greenblatt JJ, Rosenberg SA, Klein H, Berger M, Mullen CA, Ramsey WJ, Muul L, Morgan RA and Anderson WF: T lymphocyte-directed gene therapy for ADA-SCID: Initial trial results after 4 years. Science 270: 475-480, 1995.
22. Hirschhorn R, Roegner-Maniscalco V, Kuritsky L, Rosen FS: Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients. J Clin Invest 68: 1387-1393, 1981.
23. Bordignon C, Notarangelo LD, Nobili N, Ferrari G, Casorati G, Panina P, Mazzolari E, Maggioni D, Rossi C, Servida P, Ugazio AG and Mavilio F: Gene therapy in peripheral blood lymphocytes and bone marrow for ADA-immunodeficient patients. Science 270: 470-475, 1995.
24. Ferrari G, Rossini S, Giavazzi R, Maggioni D, Nobili N, Soldati M, Ungers G, Mavilio F, Gilboa E, Bordignon C: An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. Science 251: 1363-1366, 1991.
25. Kohn DB, Weinberg KI, Nolta JA, Heiss LH, Lenarsky C, Crooks GM, Hanley ME, Annett G, Brooks JS, El-Khoureiy A, Lawrence K, Wells S, Moen RC, Bastian J, Williams-Herman DE, Elder M, Wara D, Bowen T, Hershfield MS, Mullen CA, Blaese RM, Parkman R: Engraftment of gene-modified umbilical cord blood cells in neonates with adenosine deaminase deficiency. Nature Med 1: 1017-1023, 1995.
26. Karlsson S: Treatment of genetic defects in hematopoietic cell function by gene transfer. Blood 78: 2481-2492, 1991.
27. Riordan JF, Rommens JM, Kerem B-S, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou J-L Drumm MI, Iannuzzi MC, Collins FS, Tsui L-C: Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 245: 1066-1073, 1989.
28. Yoshimura K, Rosenfeld MA, Nakamura H, Scherer EM, Pavirani A, Lecocq J-P, Crystal RG: Expression of the human cystic fibrosis transmembrane conductance regulator gene in the mouse lung after in vivo intratracheal plasmid-mediated gene transfer. Nucleic Acids Res 30: 3233-3240, 1992.
29. Rosenfeld MA, Yoshimura K, Trapnell BC, Yoneyama K, Rosenthal ER, Dalemans W, Fukayama M, Bargon J, Stier LE, Stratford-Perricaudet L, Perricaudet M, Guggino WB, Pavirani A, Lecocq J-P and Crystal RG: In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68: 143-155, 1992.
30. Hyde SC, Gill DR, Higgins CF, Trezise AEO, MacVinish LJ, Cuthbert AW, Ratcliff R, Evans MJ, Colledge WH: Correction of the ion transport defect in cystic fibrosis transgenic mice by gene therapy. Nature 362: 250-255, 1993.
31. Olsen JC, Sechelski J: Use of sodium butyrate to enhance production of retroviral vectors expressing CFTR cDNA. Hum Gene Ther 6: 1195-1202, 1995.
32. Lynch C, Israel DI, Kaufman RJ, Miller AD: Sequences in the coding region of clotting FVIII act as dominant inhibitors of RNA accumulation and protein production. Hum Gene Ther 4: 259-272, 1993.
33. Chuah MKL, Vandendriessche T and Morgan RA: Development and analysis of retroviral vectors expressing human factor VIII as a potential gene therapy for hemophilia A. Hum Gene Ther 6: 1363-1377, 1995.
34. Zatloukal K, Cotten M, Berger M, Schimdt W, Wagner E, Birnstiel ML: In vivo production of human factor VIII in mice after intrasplenic implantation of primary fibroblasts transfected by receptor-mediated, adenovirus-augmented gene delivery. Proc Natl Acad Sci USA 91: 5148-5152, 1994.
35. Dwarki VJ, Belloni P, Nijjar T, Smith J, Couto L, Rabier M, Clift S, Berns A and Cohen LK: Gene therapy for hemophilia A: Production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA 92: 1023-1027, 1995.
36. Dai Y, Roman M, Naviaux RK and Verma IM: Gene therapy via primary myoblasts: Long term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci USA 89: 10892-10895, 1992.
37. Kay MA, Landen CN, Rothenberg SR, Taylor LA, Leland F, Wiehle S, Fang B, Bellinger D, Finegold M, Thompson AR, Read M, Brinkhous KM, Woo SLC: In vivo hepatic gene therapy: Complete albeit transient correction of factor IX deficiency in hemophilia B dogs. Proc Natl Acad Sci USA 91: 2353-2357, 1994.
38. Kay MA, Rothenberg S, Landen CN, Bellinger DA, Leland F, Toman C, Finegold M, Thompson AR, Read MS, Brinkhous KM and Woo SLC: In vivo gene therapy of hemophilia B: Sustained partial correction in factor IX-deficient dogs. Science 262: 117-119, 1993.
39. Fang B, Eisensmith RC, Wang H, Kay MA, Cross RE, Landen CN, Gordon G, Bellinger DA, Read MS, Hu PC, Brinkhous KM and Woo SLC: Gene therapy for hemophilia B: Host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 6: 1039-1044, 1995.
40. Dai Y, Schwarz EM, Gu D, Zhang W-W, Sarvetnick N and Verma IM: Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 92: 1401-1405, 1995.
41. Nakao N, Frodl EM, Widner H, Carlson E, Eggerding FA, Epstein CJ, Brundin P: Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. Nature Med 1: 226-231, 1995.
42. Wolff JA, Fisher LJ, Xu L, Jinnah HA, Langlais PJ, Iuvone PM, O'Malley KL, Rosenberg MB, Shimohama S, Friedmann T, Gage FH: Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease. Proc Natl Acad Sci USA 86: 9011-9014, 1989.
43. Fisher LJ, Jinnah HA, Kale LC, Higgins GA, Gage FH: Survival and function of intrastriatally grafted primary fibroblasts genetically modified to produce L-dopa. Neuron 6: 371-380, 1991.
44. Jiao S, Gurevich V and Wolff JA: Long-term correction of rat model of Parkinson's disease by gene therapy. Nature 362: 450-453, 1993.
45. Cao L, Zheng Z-C, Zhao Y-C, Jiang Z-H, Liu Z-G, Chen S-D, Zhou C-F and Liu X-Y: Gene therapy of Parkinson disease model rat by direct injection of plasmid DNA-lipofectin complex. Hum Gene Ther 6: 1497-1501, 1995.
46. During MJ, Naegele JR, O'Malley KL, Geller AI: Long-term behavioral recovery in Parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 266: 1399-1403, 1994.
47. Ikonen E, Aula P, Gron K, Tollersrud O, Halila R, Manninen T, Syvanen A-C, Pertonen L: Spectrum of mutations in aspartylglucosaminuria. Proc Natl Acad Sci USA 88: 11222-11226, 1991.
48. Enomaa N, Danos O, Peltonen L and Jalanko A: Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer. Hum Gene Ther 6: 723-731, 1995.
49. Parkman R: The application of bone marrow transplantation to the treatment of genetic diseases. Science 232: 1373-1378, 1986.
50. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO: Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci USA 87: 1913-1916, 1990.
51. Wolfe JH, Sands MS, Barker JE, Gwynn B, Rowe LB, Vogler CA and Birkenmeier EH: Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature 360: 749-753, 1992.
52. Moullier P, Bohl D, Heard J-M, Danos O: Correction of lysosomal storage in the liver and spleen of MPS VII mice by implantation of genetically modified skin fibroblasts. Nature Genet 4: 154-159, 1993.
53. Rosenfeld MA, Siegfried W, Yoshimura K, Yoneyama K, Fukayama M, Stier LE, Pääkkö PK, Gilardi P, Stratford-Perricaudet L, Perricaudet M, Jallat S, Pavirani A, Lecocq J-P and Crystal RG: Adenovirus-mediated transfer of recombinant ctl-antitrypsin gene to the lung epithelium in vivo. Science 252: 431-434, 1991.
54. Crystal RG: α1-antitrypsin deficiency, emphysema, and liver disease. J Clin Invest 85: 1343-1352, 1990.
55. Carreau M, Quilliet X, Eveno E, Salvetti A, Danos O, Heard J-M, Mezzina M and Sarasin A: Functional retroviral vector for gene therapy of xeroderma pigmentosum group D patients. Hum Gene Ther 6: 1307-1315, 1995.
56. Gözükara EM, Parris CN, Weber CA, Salazar EP, Seidman MM, Watkins JF, Prakash L, Kraemer KH: The human DNA repair gene, ERCC2 (XPD), corrects ultraviolet hypersensitivity and ultraviolet hypermutability of a shuttle vector replicated in xeroderma pigmentosum group D cells. Cancer Res 54: 3837-3844, 1994.
57. Boulikas T: Xeroderma pigmentosum and molecular cloning of DNA repair genes. Anticancer Res 16: 693-708, 1996.
58. Boulikas T: The nonuniform repair of active and inactive chromatin domains. Int J Oncol 8: 65-75, 1996.
59. Lehrman MA, Goldstein JL, Russell DW, Brown MS: Duplication of seven exons in LDL receptor gene caused by Alu-Alu recombination in a subject with familial hypercholesterolemia. Cell 48: 827-835, 1987.
60. Chowdhury JR, Grossman M, Gupta SJ, Chowdhury NR, Baker Jr JR, Wilson JM: Long term improvement of hypercholesterolemia after ex vivo gene therapy in LDLR-deficient rabbits. Science 254: 1802-1805, 1991.
61. Wilson JM, Grossman M, Raper SE, Baker JR, Newton RS and Thoene JG: Clinical protocol. Ex vivo gene therapy of familial hypercholesterolemia. Hum Gene Ther 3: 179-222, 1992.
62. Chao J, Jin L, Chen L-M, Chen VC and Chao L: Systemic and portal vein delivery of human kallikrein gene reduces blood pressure in hypersensitive rats. Hum Gene Ther 7: 901-911, 1996.
63. Cohen J: Protease inhibitors: A tale of two companies. Science 272: 1882-1883, 1996.
64. Richman DD: HIV therapeutics. Science 272: 1886-1887, 1996.
65. Bloom BR: A perspective on AIDS vaccines. Science 272: 1888-1890, 1996.
66. Baltimore D: Intracellular immunization. Nature 335: 395-396, 1988.
67. Trono D, Feinberg MB, Baltimore D: HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus. Cell 59: 113-120, 1989.
68. Malim MH, Böhnlein S, Hauber J, Cullen BR: Functional dissection of the HIV-I Rev trans-activator - Derivation of a trans-dominant repressor of Rev function. Cell 58: 205-214, 1989.
69. Venkatesh LK, Arens MQ, Subramanian T, Chinnadurai G: Selective induction of toxicity to human cells expressing human immunodeficiency virus type 1 Tat by a conditionally cytotoxic adenovirus vector. Proc Natl Acad Sci USA 87: 8746-8750, 1990.
70. Brady HJM, Miles CG, Pennington DJ, Dzierzak EA: Specific ablation of human immunodeficiency virus Tat-expressing cells by conditionally toxic retroviruses. Proc Natl Acad Sci USA 91: 365-369, 1994.
71. Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 362: 801-809, 1993.
72. Border WA, Noble NA: Targeting TGF-ß for treatment of disease. Nature Med 1: 1000-1001, 1995.
73. Nabel EG, Shum L, Pompili VJ, Yang Z-Y, San H, Shu HB. Liptay S, Gold L, Gordon D, Derynck R, Nabel GJ: Direct transfer of transforming growth factor ß1 gene into arteries stimulates fibrocellular hyperplasia. Proc Natl Acad Sci USA 90: 10759-10763, 1993.
74. Isner JM, Walsh K, Rosenfield K, Schainfeld R, Asahara T, Hogan K and Pieczek A: Clinical protocol. Arterial gene therapy for restenosis. Hum Gene Ther 7: 989-1011, 1996.
75. Takeshita S, Zheng LP, Brogi E, Kearney M, Pu L-Q, Bunting S, Ferrara N, Symes JF and Isner JM: Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic limb model. J Clin Invest 93: 662-670, 1994.
76. Leung DW, Cachianes G, Kuang W-J, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989.
77. Guzman RJ, Hirskowitz EA, Brody SL, Crystal RG, Epstein SE and Finkel T: In vivo suppression of injury-induced vascular, smooth muscle cell accumulation using adenovirus-mediated, transfer of the herpes simplex virus thymidine kinase gene. Proc Natl Acad Sci USA 91: 10732-10736, 1994.
78. Lidner V, Reidy MA: Proliferation of smooth muscle cells after vascular injury if inhibited by an antibody, against basic fibroblast growth factor. Proc Natl Acad Sci USA 88: 3739-3743, 1991.
79. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel GJ and Nabel EG: Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science 265: 781-784, 1994.
80. Chang MW, Barr E, Seltzer J, Jiang Y-Q, Nabel GJ, Nabel EG, Parmacek MS and Leiden JM: Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science 267: 518-522, 1995.
81. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ: Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA 92: 1137-1141, 1995.
82. Nabel EG, Plautz G and Nabel GJ: Site-specific gene expression in vivo by direct gene transfer into arterial wall. Science 249: 1285-1288, 1990.
83. Nabel EG, Yang Z, Plautz G, Forough R, Zhan X, Haudenschild CC, Maciag T, Nabel GJ: Recombinant fibroblast growth factor-1 promotes intimai hyperplasia and angiogenesis in arteries in vivo. Nature 362: 844-846, 1993.
84. Takeshita S, Losordo DW, Kearney M, Rossow ST and Isner JM: Time course of recombinant protein secretion after liposome-mediated gene transfer in a rabbit arterial organ culture model. Lab Invest 71: 387-391, 1994.
85. Flugelman MY, Jaklitch MT, Newman KD, Casscells W, Bratthauer GL and Dichek DA: Low level in vivo gene transfer, into the arterial wall through a perforated balloon catheter. Circulation 85: 1110-1117, 1992.
86. Lynch CM, Clowes MM, Osborne WRA, Clowes AW, Miller AD: Long-term expression of human adenosine deaminase in vascular smooth muscle cells of rats: A model for gene therapy. Proc Natl Acad Sci USA 89: 1138-1142, 1992.
87. Nabel EG, Yang Z, Liptay S, San H, Gordon D, Haudenschild CC, Nabel GJ: Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimal hyperplasia in vivo. J Clin Invest 91: 1822-1829, 1993.
88. Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, Møller NPH, Risau W and Ullrich A: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835-846, 1993.
89. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, Feder J and Connolly DT: Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309-1312, 1989.
90. Leung DW, Cachianes G, Kuang W-J, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306-1309, 1989.
91. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC and Abraham JA: The human gene for vascular, endothelial growth factor. Multiple protein forms are encoded. through alternative exon splicing. J Biol Chem 266: 11947-11954, 1991.
92. Senger DR, van de Water L, Brown LF, Nagy JA, Yeo K-T, Yeo T-K, Berse B, Jackman RW, Dvorak AM and Dvorak HF: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12: 303-324, 1993.
93. Suzuki K, Hayashi N, Miyamoto Y, Yamamoto M, Ohkawa K, Ito Y, Sasaki Y, Yamaguchi Y, Nakase H, Noda K, Enomoto N, Arai K, Yamada Y, Yoshihara H, Tujimura T, Kawano K, Yoshikawa K and Kamada T: Expression of vascular permeability factor/vascular endothelial factor in human hepatocellular carcinoma. Cancer Res 56: 3004-3009, 1996.
94. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359: 845-848, 1992.
95. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992.
96. Liotta LA, Steeg PS and Stetler-Stevenson WG: Review. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 64: 327-336, 1991.
97. Folkman J and Klagsbrun M: Angiogenic factors. Science 235: 442-447, 1987.
98. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N and Williams LT: The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 255: 989-991, 1992.
99. Millauer B, Wizigmann-Voos S, Schnürch H, Martinez R, Møller NPH, Risau W and Ullrich A: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835-846, 1993.
100. Christofori G, Naik P and Hanahan D: Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 9: 1760-1770, 1995.
101. Fong G, Rossant J, Gertsenstein M, Breitman ML: Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70, 1995.
102. Shalaby F, Rossant J, Yamaguchi TP, Gertsenstein M, Wu X, Breitman ML, Schuh AC: Failure of blood island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66, 1995.
103. Saleh M: Ectopic expression of vascular endothelial growth factor (VEGF) by C6 glioma cells does not increase tumour growth in vivo despite an increase in angiogenesis. Int J Oncol 9: 33-41, 1996.
104. Saleh M, Stacker SA, Wilks AF: Inhibition of growth of C6 glioma cells in vivo by expression of antisense Vascular Endothelial Growth Factor (VEGF) sequence. Cancer Res 56: 393-401, 1996.
105. Markowitz S, Wang J, Myeroff L, Parsons R, Sun L, Lutterbaugh J, Fan RS, Zborowska E, Kinzler KW, Vogelstein B, Brattain M, Willson JKV: Inactivation of the Type II TGF-ß receptor in colon cancer cells with microsatellite instability. Science 268: 1336-1338, 1995.
106. Ross R: Genetically modified mice as models of transplant atherosclerosis. Nature Med 2: 527-528, 1995.
107. Nowak R: Entering the postgenome era. Science 270: 368-371, 1995.
108. Boulikas T: A model of transcription/replication enhancers. Oncol Rep 2: 171-181, 1995.
109. Boulikas T: Chromatin domains and prediction of MAR sequences. Int Rev Cytol 162A: 279-388, 1995.
110. Boulikas T: Nuclear localization signal peptides for the import of plasmid DNA in gene therapy. Int J Oncol (In press).
111. Spandidos DA, Zoumpourlis V, Zachos G, Toas SH, Halazonetis TD: Specific recognition of a transcriptional element within the human H-ras proto-oncogene by the p53 tumor suppressor. Int J Oncol 7: 1029-1034, 1995.
112. Zoumpourlis V, Zachos G, Halazonetis TD, Ergazaki M, Spandidos DA: Binding of wild-type and mutant forms of p53 protein from human tumors to a specific DNA sequence of the first intron of the H-ras oncogene. Int J Oncol 7: 1035-1041, 1995.